Altimmune, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 27, 2024. Altimmune is a clinical-stage biopharmaceutical company developing treatments for obesity and liver diseases; it has no approved products and has not generated product-sales revenue.
Financial results and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $0.426 million | $(0.068) million |
| Research and development expense | $65.8 million | $70.5 million |
| General and administrative expense | $18.1 million | $17.1 million |
| HepTcell impairment charge | $12.4 million | None |
| Operating loss | $(95.9) million | $(87.7) million |
| Interest income | $7.4 million | $2.9 million |
| Net loss | $(88.4) million | $(84.7) million |
| Net loss per share, diluted | $(1.66) | $(1.81) |
| Net cash used in operations | $75.8 million | $62.6 million |
- Revenue primarily reflects grant and contract adjustments, not product sales. The filing does not provide a meaningful operating margin for a company without commercial product revenue.
- At year-end, cash, cash equivalents, restricted cash and short-term investments totaled $197.9 million, compared with $184.9 million in 2022. Current assets were $209.6 million and current liabilities $12.1 million.
- Total liabilities were $16.5 million, including lease obligations; the filing reports no material conventional borrowing balance. Management said available resources, together with expected tax refunds and R&D incentive receipts, should fund operations for at least 12 months from issuance of the financial statements, but not through completion of the trials needed for approval and commercialization.
- Financing provided $86.1 million of net cash, chiefly from an at-the-market (ATM) stock offering. The company sold 20.45 million shares for approximately $86.6 million net proceeds; $60.6 million of ATM capacity remained at year-end. Shares outstanding rose from 49.2 million to 70.7 million.
Material changes and business developments
- R&D expense fell 7%, mainly as earlier pemvidutide and HepTcell studies wound down; this was partly offset by the MASH Phase 2b IMPACT trial ramp-up and manufacturing costs. The $12.4 million non-cash HepTcell impairment contributed to the higher operating loss.
- Higher interest income partly offset operating losses. Net loss increased 4%, while loss per share narrowed because of the higher weighted-average share count.
- Pemvidutide, the lead GLP-1/glucagon dual agonist, produced topline 48-week MOMENTUM Phase 2 obesity-trial mean weight losses of 10.3%, 11.2% and 15.6% at 1.2 mg, 1.8 mg and 2.4 mg, respectively, versus 2.2% with placebo. At 2.4 mg, 51.8% of analyzed participants achieved at least 15% weight loss and 32.1% at least 20%.
- Tolerability is an important counterpoint: adverse-event-related discontinuations were 5.1%, 19.2% and 19.6% at the three pemvidutide doses, versus 6.2% with placebo. Nausea and vomiting were common, mostly mild to moderate; the 2.4 mg group had one drug-related serious adverse event. No major adverse cardiovascular events were reported in the trial.
- In a 12-week Phase 1b MASLD study, pemvidutide met the primary liver-fat endpoint; the 1.8 mg group showed a 68.5% mean relative reduction in liver fat. These are earlier-stage findings and do not establish clinical benefit on liver outcomes.
- The company initiated the biopsy-driven IMPACT Phase 2b MASH trial in 2023, targeting approximately 190 participants. Topline 24-week results were expected in the first quarter of 2025. FDA granted pemvidutide fast track designation for MASH in October 2023; this does not assure approval or a faster review.
- HepTcell’s Phase 2 results were later deemed insufficient for further development, and the company announced discontinuation on March 27, 2024. The filing recorded the impairment at December 31, 2023 based on preliminary trial data analyzed in December.
Outlook, risks and unusual items
- Management expects substantial ongoing R&D spending and operating losses. Future funding may be needed; additional equity financing could dilute shareholders, while debt or partnerships could impose restrictions or require licensing rights.
- Key risks include clinical-trial failure or delay, safety and tolerability, regulatory uncertainty, competition in obesity and MASH, reliance on third-party manufacturers and trial operators, and uncertainty around reimbursement and pricing.
- Research and manufacturing supply constraints, labor availability, macroeconomic conditions, cybersecurity and data privacy, intellectual-property protection, and the ability to secure strategic partners are also cited risks.
- The company has no manufacturing facilities and relies on third parties for clinical supply. It reports no material legal proceedings. Its financial statements received an unqualified audit opinion; management assessed disclosure controls and internal control over financial reporting as effective, while the auditor did not provide an opinion on internal-control effectiveness.
- The company reported a $466.3 million accumulated deficit and no product revenue. It also disclosed U.S. federal and state NOL carryforwards of approximately $152.7 million and $143.3 million, respectively, subject to potential utilization limits.
Important facts for investors to verify
- Review final, complete MOMENTUM data, including durability of weight loss, dose-specific discontinuations, and the balance of benefits and tolerability.
- Track IMPACT enrollment, prespecified biopsy endpoints, trial progress and the expected 2025 topline readout; distinguish biomarker results from demonstrated clinical outcomes.
- Reassess cash runway against actual operating burn, trial costs and expected incentive or tax receipts, and monitor further ATM sales, share-count growth and dilution.
- Confirm the implications of HepTcell’s discontinuation and impairment, and whether management reallocates resources or pursues partnerships.
- Monitor manufacturing capacity, regulatory feedback, competitive trial results and future financing needs; clinical-stage outcomes and management’s runway estimates remain uncertain.